Dornase alfa for cystic fibrosis
In patients with cystic fibrosis thick viscous secretions, colonised by bacteria, accumulate in the respiratory tract and cause airway obstruction and recurrent exacerbations of infection. Standard treatment includes physiotherapy and antibiotics. Dornase alfa (Pulmozyme – Genentech/Roche) has recently been licensed in the UK for the longterm treatment of patients with cystic fibrosis aged over 5 years who have a forced vital capacity (FVC) greater than 40% of predicted. The manufacturer claims that dornase alfa, the first drug of its kind, produces ‘an improvement of pulmonary function’ and ‘a reduction in days requiring administration of parenteral antibiotics’.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Milla, C. E
(1998). Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax
53: 1014-1017
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Gastrointestinal system
-
Respiratory system
-
Infections
-
Malignant disease and immunosuppression
-
Gastroenterology
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
